Vijay Pande, founding investor of venture capitalist company Andreessen Horowitz’s Bio + Health fund, discusses advances in biopharmaceutical merger and acquisition (M&A) activity, gene editing, and artificial intelligence (AI) applications in life sciences. He suggests AI shows promise in unlocking the complexities of human disease biology, potentially enhancing the success rate of clinical trials and thereby lowering costs and speeding up drug development. Pande also indicates that M&A activity is expected to surge in 2024.
UK’s Legal Aid Agency Experiences Cyberattack
A UK Ministry of Justice executive agency was targeted in a cyberattack, compromising its systems. The incident highlights vulnerabilities in cybersecurity, prompting a review of
